Kojiro Mashino

543 citations
9 papers · 438 indexed · h-index 6
Topics
HER2/EGFR in Cancer Research (3 papers)Cancer Treatment and Pharmacology (3 papers)PI3K/AKT/mTOR signaling in cancer (3 papers)
Partner nations
Japan

In The Last Decade

Kojiro Mashino

8 papers receiving 432 citations

Peers

Kojiro Mashino
Comparison fields: 5 of 53
  • Molecular Biology 300
  • Oncology 195
  • Pulmonary and Respiratory Medicine 99
  • Genetics 86
  • Cancer Research 85
Replace Myles C. Hodgson with:
Myles C. Hodgson United States
Qianfeng Shi China
Crystal Cornelius United States
Josefine Bostner Sweden
Dabei Tang China
Lin‐wen Wu China
Qing-Yun Chong Singapore
J M Knowlden United Kingdom
Ma Xiaoling United States
Sébastien L. Floor Belgium
Kojiro Mashino relative to Myles C. Hodgson United States Myles C. Hodgson's profile →
Citations per field
00.5×1.5×2.2×
Myles C. Hodgson · 1×
Citations per year

Countries citing papers authored by Kojiro Mashino

Since Specialization
Citations

This map shows the geographic impact of Kojiro Mashino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kojiro Mashino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kojiro Mashino more than expected).

Fields of papers citing papers by Kojiro Mashino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kojiro Mashino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kojiro Mashino. The network helps show where Kojiro Mashino may publish in the future.

Co-authorship network of co-authors of Kojiro Mashino

This figure shows the co-authorship network connecting the top 25 collaborators of Kojiro Mashino. A scholar is included among the top collaborators of Kojiro Mashino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kojiro Mashino. Kojiro Mashino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
#WorkIndexed citations
1 5
2 8
3 11
4 3
5
[The efficacy and safety of docetaxel for elderly advanced breast cancer patients].
2
6 163
7 97
8 0
9 149

About Kojiro Mashino

Kojiro Mashino is a scholar working on Oncology, Hematology and Cancer Research, having authored 9 papers that have together received 438 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (195 citations), Cancer Research (85 citations) and Molecular Biology (300 citations). Kojiro Mashino has collaborated with scholars based in Japan. Frequent co-authors include Yoshihiro Kakeji, Yoshihiko Maehara, Yasue Kimura, Eiji Oki, Hideo Baba, Eriko Tokunaga, Shinji Ohno, Masaru Morita, Akemi Kataoka and Naoyuki Ueda. Their work appears in journals such as International Journal of Cancer, European Journal of Cancer and Surgery Today.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026